Endothelial Dysfunction in Diabetes

Avogaro, Angelo; Albiero, Mattia; Menegazzo, Lisa; Kreutzenberg, Saula de; Fadini, Gian Paolo

doi:10.2337/dc11-s239

Cited by 418 publications

(307 citation statements)

References 38 publications

Supporting

Mentioning

283

Contrasting

Unclassified

Order By: Relevance

“…Increasing evidence suggests that diabetes mellitus, hypercholesterolemia, hypertension, and smoking lead to atherosclerosis as well as endothelial dysfunction [31,32]. The main finding in the current study that non diabetic patient with ischemic stroke had significantly higher values of serum NO compared to diabetic group .On the contrary; there were highly significant elevated serum ET-1 levels in diabetic group as compared to non-diabetic group.…”

contrasting

confidence: 34%

“…Our study explored that after adjusted for the traditional risk factors, serum NO and ET-1 levels were statistically significant predictor of ischemic stroke among patients with ischemic stroke. Endothelial dysfunction seems to precede the development of diabetes, as impaired endothelium-dependent vasodilation was observed in healthy non-diabetic subjects who have a first degree relative with T2DM [32], as well as in subjects with impaired glucose tolerance [31].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Endothelial Hemostasis; Serum Nitric Oxide and Endothelin-1 Levels in Ischemic Cerebrovascular Stroke With or Without Type 2 Diabetes.

Rashad¹,

Elantouny²,

Shal³

et al. 2017

IJAR

View full text Add to dashboard Cite

endothelial dysfunction; ischemic stroke; endothelin-1; nitric oxide.well as the second leading cause of mortality worldwide. The role of endothelial dysfunction in stroke is critical. Nitric oxide (NO) and endothelin-1 (ET-1) which are produced in endothelial cells are leading molecules regulating vascular function. Aim of the work: the aim of our study was to estimate serum nitric oxide and endothelin-1 levels as biomarkers of endothelial function in ischemic cerebrovascular stroke with or without type 2 diabetes mellitus (T2DM). Methods: A cross-section study included 100 patients with ischemic stroke who were stratified into two groups according to their fasting blood glucose into non-diabetic group (n=45) and diabetic group (n=55). The levels of serum NO were determined calorimetrically. Serum ET-1 concentrations were also estimated by enzyme immunoassay technique. Results: Our results showed that non diabetic patients with ischemic stroke had significantly higher values of serum NO compared to diabetic group .On the contrary; there was highly significant elevated serum ET-1 levels in diabetic group compared to non-diabetic group. After adjusted for the traditional risk factors, logistic regression analysis test demonstrated that both serum NO and ET-1 levels were statistically significant predictors of insulin resistance among patients with ischemic stroke. Linear regression analysis test showed that serum NO levels were independently correlated with high density cholesterol (HDL.C) values and systolic blood pressure. Regarding serum ET-1 levels, they were independently correlated with homeostasis model assessment of insulin resistance index (HOMA-IR) and waist/hip ratio (WHR) in patients with ischemic stroke. Conclusions: Both serum endothelin-1 and nitric oxide levels could be useful diagnostic biomarkers predicting insulin resistance among patients with ischemic stroke.

show abstract

contrasting

confidence: 34%

mentioning

confidence: 99%

Assessment of Endothelial Hemostasis; Serum Nitric Oxide and Endothelin-1 Levels in Ischemic Cerebrovascular Stroke With or Without Type 2 Diabetes.

Rashad¹,

Elantouny²,

Shal³

et al. 2017

IJAR

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence suggests that T2DM can negatively affect cardiovascular (CV) status by different pathogenic processes, which include accelerated atherosclerosis, as well as abnormalities in inflammatory pathways and in endothelial, myocardial, and platelet function [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Theeffect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risk in Type 2 Diabetes Mellitus

Tolba

Khashab

Said

2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: The aim of this study was is to investigate the proposed beneficial cardiovascular effects of a novel class of antidiabetic drugs named; dipeptidyl peptidase 4 inhibitors. In this study, we compared the effect of using add-on therapy of vildagliptin (dipeptidyl peptidase-4 inhibitor; DPP-4i) and gliclazide (sulphonylurea; SU) to that when using gliclazide monotherapy in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) on different cardiovascular outcomes.Methods: A total of 60 patients diagnosed with T2DM, and ACS were randomly recruited into two treatment groups each of 30 patients to receive either gliclazide monotherapy (SU) or vildagliptin (DPP4i)+gliclazide (SU) add-on therapy, administered in a double-blind fashion. Outpatient visits were scheduled at 3, 6, and 12 mo where patient was reevaluated for cardiovascular (CV) outcomes and followed up for any arising cardiovascular complication. Results:The vildagliptin (DPP4i) plus gliclazide (SU) add-on therapy group have significantly shown more improved glycemic control, lipid profile and ventricular performance compared to gliclazide (SU) monotherapy group with p values<0.05. Conclusion:Vildagliptin as a DPP4i provides favourable cardiovascular effects beyond glucose control. Yet, its long-term safety and efficacy data still needs further investigations.

show abstract

“…39,40 Thus, hypertriglyceridemia may represent an additional factor that exacerbates these pathological processes and it should be taken into consideration, especially if present in early pregnancy. 41 During the Banting Lecture in 1980, Norbert Freinkel 42 suggested that nutrients other than glucose could be linked with excessive fetal growth.…”

Section: Resultsmentioning

confidence: 99%

Association between preconceptional treatment with insulin pumps and improved metabolic status in early pregnancy in women with type 1 diabetes

Gutaj¹,

Zawiejska²,

Brązert³

et al. 2015

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

INTRODUCTION An adverse intrauterine environment in early pregnancy in women with type 1 diabetes is associated with several perinatal complications including spontaneous abortions, fetal congenital defects, and preeclampsia.ObjECTIvEs We compared metabolic parameters in the first trimester of pregnancy between women with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) and those treated with multiple daily injections (MDI).PATIENTs AND mEThODs A total of 168 women in the first trimester of pregnancy (33 using CSII and 135 using MDI) were enrolled in this cross-sectional single-center study. Anthropometric parameters, fasting serum levels of hemoglobin A 1c (HbA 1c ), lipid profile, and estimated glucose disposal rate (eGDR) were determined. REsULTsPatients did not differ in gestational or maternal age, diabetes duration, and the frequency of planned pregnancies. Women using CSII before pregnancy had lower body mass index and waist-to-hip ratio than those using MDI (22.3 vs 23.3 and 0.77 vs 0.79, respectively, P = 0.01). A similar number of women had hypertension; however, the CSII group had lower diastolic blood pressure (P = 0.02). Moreover, the CSII group had a significantly lower insulin requirement (0.54 vs 0.63 units/kg; P = 0.02), significantly higher eGDR (11.3 vs 10.5 mg/kg/min; P = 0.0007), and significantly lower serum triglyceride levels (53.1 vs 61.8 mg/dl; P = 0.004). In a multiple regression analysis, CSII therapy was associated with higher eGDR, lower HbA 1c , and lower serum triglyceride levels.CONCLUsIONs The use of CSII before pregnancy in patients with type 1 diabetes is associated with better metabolic profile in the first trimester. ORIGINAL ARTICLEAssociation between preconceptional treatment with insulin pumps and improved metabolic status in early pregnancy in women with type 1 diabetes Paweł Gutaj, Agnieszka Zawiejska, Jacek Brązert, Ewa Wender-Ożegowska (7 patients). Two patients refused to participate in the study.All study participants were Caucasians. They were all treated with functional intensive therapy before pregnancy; 135 patients received MDI and 33-CSII. All CSII users had been using this method of therapy for at least 6 months. A basal-bolus protocol used in patients on MDI involved 3 injections of short-acting insulin analog before meals and 1 or 2 injections of intermediate-acting insulin at bedtime or at bedtime and in the morning. Women on CSII received short-acting insulin analog (continuous basal rate and 3 premeal boluses).Of all patients, 61 women using MDI and 20 women using CSII received prepregnancy counseling delivered by a diabetologist or an obstetrician with a special interest in diabetic pregnancy. These data were self-reported by participants. The remaining women received standard care for nonpregnant patients with type 1 diabetes delivered by diabetologists as recommended by the PTD. According to the PTD, blood glucose and HbA 1c targets for women planning their pregnancies or already pregnant compared with those nonp...

show abstract

Endothelial Dysfunction in Diabetes

Cited by 418 publications

References 38 publications

Assessment of Endothelial Hemostasis; Serum Nitric Oxide and Endothelin-1 Levels in Ischemic Cerebrovascular Stroke With or Without Type 2 Diabetes.

Assessment of Endothelial Hemostasis; Serum Nitric Oxide and Endothelin-1 Levels in Ischemic Cerebrovascular Stroke With or Without Type 2 Diabetes.

Theeffect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risk in Type 2 Diabetes Mellitus

Association between preconceptional treatment with insulin pumps and improved metabolic status in early pregnancy in women with type 1 diabetes

Contact Info

Product

Resources

About